Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Taxes: 2014-2018

Historic Current Taxes for Enanta Pharmaceuticals (ENTA) over the last 2 years, with Dec 2018 value amounting to $5.9 million.

  • Enanta Pharmaceuticals' Current Taxes fell 42.89% to $5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.9 million, marking a year-over-year decrease of 42.89%. This contributed to the annual value of $1.4 million for FY2018, which is 85.07% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Current Taxes stood at $5.9 million for Q4 2018, which was up 322.05% from $1.4 million recorded in Q3 2018.
  • In the past 5 years, Enanta Pharmaceuticals' Current Taxes registered a high of $16.9 million during Q4 2014, and its lowest value of $1.2 million during Q3 2015.
  • For the 3-year period, Enanta Pharmaceuticals' Current Taxes averaged around $6.0 million, with its median value being $5.9 million (2018).
  • Its Current Taxes has fluctuated over the past 5 years, first spiked by 31.99% in 2016, then crashed by 85.07% in 2018.
  • Over the past 5 years, Enanta Pharmaceuticals' Current Taxes (Quarterly) stood at $16.9 million in 2014, then crashed by 70.76% to $4.9 million in 2015, then surged by 31.99% to $2.9 million in 2016, then reached $10.3 million in 2017, then plummeted by 42.89% to $5.9 million in 2018.
  • Its Current Taxes stands at $5.9 million for Q4 2018, versus $1.4 million for Q3 2018 and $5.4 million for Q1 2018.